Content about Bipolar spectrum

March 7, 2012
Forest, Pierre Fabre drug 'significantly' reduced depression symptoms

A drug under development by Forest Labs and Pierre Fabre "significantly" reduced symptoms of major depressive disorder, the companies said Wednesday.

NEW YORK — A drug under development by Forest Labs and Pierre Fabre "significantly" reduced symptoms of major depressive disorder, the companies said Wednesday.

New York-based Forest and Paris-based Pierre Fabre announced results of a phase-3 trial of levomilnacipran, saying the drug showed reductions in symptoms as early as one week after treatment was started. The companies expect results of another phase-3 trial of the drug this spring.

May 20, 2011
Mood disorders may be precursor to diabetes in Latinos, study finds

Such mood disorders as anxiety and depression may be a precursor to diabetes in Latinos, according to a study by University of California at San Diego researchers scheduled for presentation at the American Psychiatric Association’s annual meeting in Honolulu.

NEW YORK — Such mood disorders as anxiety and depression may be a precursor to diabetes in Latinos, according to a study by University of California at San Diego researchers scheduled for presentation at the American Psychiatric Association’s annual meeting in Honolulu.

As reported in the Los Angeles Times, the researchers found that while Latinos have higher-than-average rates of diabetes, they also seem to have higher-than-average risk of having both diabetes and a mood disorder.

January 28, 2011
Depressive diabetics' spouses also experience distress, study finds

Spouses of older patients with diabetes tend to experience distress if the diabetic patient has symptoms of depression, according to a new study.

WEST LAFAYETTE, Ind. — Spouses of older patients with diabetes tend to experience distress if the diabetic patient has symptoms of depression, according to a new study.

January 24, 2011
Viibryd gets FDA approval

The Food and Drug Administration has approved a new drug for treating major depressive disorder, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating major depressive disorder, the agency said Friday.

The FDA announced the approval of Viibryd (vilazodone hydrochloride), made by New Haven, Conn.-based PGxHealth.

September 8, 2010
FDA approves expanded use of Saphris

Merck's supplemental drug applications for its atypical antipsychotic received approval from the Food and Drug...

WHITEHOUSE STATION, N.J. Merck's supplemental drug applications for its atypical antipsychotic received approval from the Food and Drug Administration, the drug maker said.

Saphris now is indicated for the treatment of schizophrenia in adults, as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, and as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, Merck said.

August 30, 2010
Study: SAMe may benefit patients taking antidepressants

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital suggested...

BOSTON A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital suggested that the dietary supplement S-adenosylmethionine (SAMe) can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication, Pharmavite announced Tuesday.